Although patients with germline and mosaic DICER1 mutations are at risk for metachronous, bilateral SLCTs [8,9,15,16], predisposing DICER1 mutations have been associated with improved recurrence-free and overall survival compared to tumor-limited mutations [16]. Here, DICER1 is linked to neoplasm.